Receptor-targeted iron oxide nanoparticles for molecular MR imaging of inflamed atherosclerotic plaques

Biomaterials

Volumn 32, Issue 29, 2011, Pages 7209-7216

  Tu, Chuqiao ^a   Ng, Thomas S C ^b   Sohi, Hargun K ^b   Palko, Heather A ^c   House, Adrian ^a   Jacobs, Russell E ^b   Louie, Angelique Y ^a  

^a University of California   (United States)

^b CALIFORNIA INSTITUTE OF TECHNOLOGY   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Imaging agents; Inflammation; Macrophages; Molecular imaging; MRI (magnetic resonance imaging); Nanoparticles

Indexed keywords

ATHEROSCLEROTIC PLAQUE; CONTRAST AGENT; DETECTION AND DIAGNOSIS; DEXTRAN SULFATES; HYDRODYNAMIC DIAMETER; IMAGING AGENT; IN-VIVO; INFLAMMATION; INJURY MODELS; INTRAVENOUS INJECTIONS; IRON OXIDE NANOPARTICLE; MOLECULAR IMAGING; MONO-DISPERSED; MR IMAGING; MRI (MAGNETIC RESONANCE IMAGING); RELAXIVITY; SCAVENGER RECEPTOR; SIGNAL LOSS; SULFUR TRIOXIDE; VULNERABLE PLAQUES;

DEXTRAN; IRON; MACROPHAGES; MAGNETIC RESONANCE IMAGING; MAMMALS; NANOMAGNETICS; NANOPARTICLES; RESONANCE; SULFUR;

IRON OXIDES;

DEXTRAN SULFATE; IRON OXIDE; NANOPARTICLE; SCAVENGER RECEPTOR A; SULFUR TRIOXIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATHEROSCLEROTIC PLAQUE; CAROTID ARTERY INJURY; CONTROLLED STUDY; HUMAN; HUMAN CELL; HYDRODYNAMICS; IN VIVO STUDY; MACROPHAGE; MOLECULAR IMAGING; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL;

ANIMALS; APOLIPOPROTEINS E; BIOCOMPATIBLE MATERIALS; CELL LINE; FERRIC COMPOUNDS; HUMANS; MAGNETIC RESONANCE IMAGING; MATERIALS TESTING; METAL NANOPARTICLES; MICE; MICE, KNOCKOUT; MOLECULAR STRUCTURE; PARTICLE SIZE; PLAQUE, ATHEROSCLEROTIC;

EID: 79960842466     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2011.06.026     Document Type: Article

References (43)

1. Fuster V., Lois F., Franco M. Early identification of atherosclerotic disease by noninvasive imaging. Nat Rev Cardiol 2010, 7:327-333.
2. Wickline S.A., Neubauer A.M., Winter P.M., Caruthers S.D., Lanza G.M. Molecular imaging and therapy of atherosclerosis with targeted nanoparticles. J Magn Reson Imaging 2007, 25:667-680.
3. Cyrus T., Lanza G.M., Wickline S.A. Molecular imaging by cardiovascular MR. J Cardiovasc Magn Reson 2007, 9:827-843.
4. Rudd J.H.F., Hyafil F., Fayad Z.A. Inflammation imaging in atherosclerosis. Arterioscler Thromb Vasc Biol 2009, 29:1009-1016.
5. Shaw S.Y. Molecular imaging in cardiovascular disease: targets and opportunities. Nat Rev Cardiol 2009, 6:569-579.
6. Winter P.M., Caruthers S.D., Lanza G.M., Wickline S.A. Quantitative cardiovascular magnetic resonance for molecular imaging. J Cardiov Magn Reson 2010, 12. Article Number: 62.
7. Sosnovik D.E., Nahrendorf M., Weissleder R. Molecular magnetic resonance imaging in cardiovascular medicine. Circulation 2007, 115:2076-2086.
8. Terreno E., Castelli D.D., Viale A., Aime S. Challenges for molecular magnetic resonance imaging. Chem Rev 2010, 110:3019-3042.
9. Geraldes C., Laurent S. Classification and basic properties of contrast agents for magnetic resonance imaging. Contrast Media Mol Imaging 2009, 4:1-23.
10. Cormode D.P., Skajaa T., Fayad Z.A., Mulder W.J.M. Nanotechnology in medical imaging probe design and applications. Arterioscler Thromb Vasc Biol 2009, 29:992-1000.
11. Qiao R.R., Yang C.H., Gao M.Y. Superparamagnetic iron oxide nanoparticles: from preparations to in vivo MRI applications. J Mater Chem 2009, 19:6274-6293.
12. Croons V., Martinet W., De Meyer G.R.Y. Selective removal of macrophages in atherosclerotic plaques as a pharmacological approach for plaque stabilization: benefits vs. potential complications. Curr Vasc Pharmacol 2010, 8:495-508.
13. Osborn E.A., Jaffer F.A. Advances in molecular imaging of atherosclerotic vascular disease. Curr Opin Cardiol 2008, 23:620-628.
14. Tang T.Y., Muller K.H., Graves M.J., Li Z.Y., Walsh S.R., Young V., et al. Iron oxide particles for atheroma imaging. Arterioscler Thromb Vasc Biol 2009, 29:1001-1008.
15. Sadat U., Li Z.Y., Graves M.J., Tang T.Y., Gillard J.H. Noninvasive imaging of atheromatous carotid plaques. Nat Clin Pract Cardiovasc Med 2009, 6:200-209.
16. Gustafsson B., Youens S., Louie A.Y. Development of contrast agents targeted to macrophage scavenger receptors for MRI of vascular inflammation. Bioconjug Chem 2006, 17:538-547.
17. Tu C.Q., Ma X.C., Pantazis P., Kauzlarich S.M., Louie A.Y. Paramagnetic, silicon quantum dots for magnetic resonance and two-photon imaging of macrophages. J Am Chem Soc 2010, 132:2016-2023.
18. Jarrett B.R., Correa C., Ma K.L., Louie A.Y. In vivo mapping of vascular inflammation using multimodal imaging. PLoS One 2010, 5. Article Number: e13254.
19. de Winther M.P.J., van Dijk K.W., Havekes L.M., Hofker M.H. Macrophage scavenger receptor class A - A multifunctional receptor in atherosclerosis. Arterioscler Thromb Vasc Biol 2000, 20:290-297.
20. Jarrett B.R., Frendo M., Vogan J., Louie A.Y. Size-controlled synthesis of dextran sulfate coated iron oxide nanoparticles for magnetic resonance imaging. Nanotechnology 2007, 18. Article Number: 035603.
21. Tu C.Q., Louie A.Y. Photochromically-controlled, reversibly-activated MRI and optical contrast agent. Chem Commun 2007, 1331-1333.
22. Kumar A., Hoover J.L., Simmons C.A., Lindner V., Shebuski R.J. Remodeling and neointimal formation in the carotid artery of normal and P-selectin-deficient mice. Circulation 1997, 96:4333-4342.
23. Heinze T., Liebert T., Heublein B., Hornig S. Functional polymers based on dextran. Adv Polym Sci 2006, 205:199-291.
24. Mahner C., Lechner M.D., Nordmeier E. Synthesis and characterisation of dextran and pullulan sulphate. Carbohydr Res 2001, 331:203-208.
25. Papy-Garcia D., Barbier-Chassefiere V., Rouet V., Kerros M.E., Klochendler C., Tournaire M.C., et al. Nondegradative sulfation of polysaccharides. synthesis and structure characterization of biologically active heparan sulfate mimetics. Macromolecules 2005, 38:4647-4654.
26. Wondraczek H., Pfeifer A., Heinze T. Synthetic photocrosslinkable polysaccharide sulfates. Eur Polym J 2010, 46:1688-1695.
27. Obeidat W.M., Schwabe K., Muller R.H., Keck C.M. Preservation of nanostructured lipid carriers (NLC). Eur J Pharm Biopharm 2010, 76:56-67.
28. Greaves D.R., Gordon S. The macrophage scavenger receptor at 30 years of age: current knowledge and future challenges. J Lipid Res 2009, 50:S282-S286.
29. Babaev V.R., Gleaves L.A., Carter K.J., Suzuki H., Kodama T., Fazio S., et al. Reduced atherosclerotic lesions in mice deficient for total or macrophage-specific expression of scavenger receptor-A. Arterioscler Thromb Vasc Biol 2000, 20:2593-2599.
30. Gossuin Y., Gillis P., Hocq A., Vuong Q.L., Roch A. Magnetic resonance relaxation properties of superparamagnetic particles. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2009, 1:299-310.
31. Tu C., Nagao R., Louie A.Y. Multimodal magnetic-resonance/optical-imaging contrast agent sensitive to NADH. Angew Chem Int Ed Engl 2009, 48:6547-6551.
32. O'Brien J., Wilson I., Orton T., Pognan F. Investigation of the Alamar Blue (resazurin) fluorescent dye for the assessment of mammalian cell cytotoxicity. Eur J Biochem 2000, 267:5421-5426.
33. Muller K., Skepper J.N., Posfai M., Trivedi R., Howarth S., Corot C., et al. Effect of ultrasmall superparamagnetic iron oxide nanoparticles (Ferumoxtran-10) on human monocyie-macrophages in vitro. Biomaterials 2007, 28:1629-1642.
34. Metz S., Bonaterra G., Rudelius M., Settles M., Rummeny E.J., Daldrup-Link H.E. Capacity of human monocytes to phagocytose approved iron oxide MR contrast agents in vitro. Eur Radiol 2004, 14:1851-1858.
35. Schulze E., Ferrucci J.T., Poss K., Lapointe L., Bogdanova A., Weissleder R. Cellular uptake and trafficking of a prototypical magnetic iron-oxide label in-vitro. Invest Radiol 1995, 30:604-610.
36. Mailander V., Lorenz M.R., Holzapfel V., Musyanovych A., Fuchs K., Wiesneth M., et al. Carboxylated superparamagnetic iron oxide particles label cells intracellularly without transfection agents. Mol Imaging Biol 2008, 10:138-146.
37. Sun C., Lee J.S.H., Zhang M.Q. Magnetic nanoparticles in MR imaging and drug delivery. Adv Drug Deliv Rev 2008, 60:1252-1265.
38. Sosnovik D.E., Caravan P. Molecular MRI of atherosclerotic plaque with targeted contrast agents. Curr Cardiovasc Imaging Rep 2009, 2:87-94.
39. Nahrendorf M., Zhang H.W., Hembrador S., Panizzi P., Sosnovik D.E., Aikawa E., et al. Nanoparticle PET-CT imaging of macrophages in inflammatory atherosclerosis. Circulation 2008, 117:379-387.
40. Uppal R., Caravan P. Targeted probes for cardiovascular MRI. Future Med Chem 2010, 2:451-470.
41. Amirbekian V., Lipinski M.J., Briley-Saebo K.C., Amirbekian S., Aguinaldo J.G.S., Weinreb D.B., et al. Detecting and assessing macrophages in vivo to evaluate atherosclerosis noninvasively using molecular MRI. Proc Natl Acad Sci U S A 2007, 104:961-966.
42. Choudhury R.P., Fisher E.A. Molecular imaging in atherosclerosis, thrombosis, and vascular inflammation. Arterioscler Thromb Vasc Biol 2009, 29:983-991.
43. Thorek D.L.J., Chen A., Czupryna J., Tsourkas A. Superparamagnetic iron oxide nanoparticle probes for molecular imaging. Ann Biomed Eng 2006, 34:23-38.